Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Marketing Status Prescription; Discontinued
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.000505%Not Available
Skin wound12.01.06.015; 23.03.11.0220.000303%Not Available
Meniscus injury12.04.03.008; 15.07.03.0060.003839%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000707%Not Available
Large intestine benign neoplasm07.20.01.013; 16.05.01.0040.000303%Not Available
Idiopathic orbital inflammation06.04.11.0020.000303%Not Available
Chronic papillomatous dermatitis12.02.16.002; 23.01.04.0050.000303%Not Available
Lumbosacral radiculopathy17.10.03.0050.001313%Not Available
Intracranial mass17.11.01.0170.000202%Not Available
Spinal flattening15.10.04.0110.000303%Not Available
The 49th Page    First    Pre   49    Total 49 Pages